PolmoniAMO_INGL

PolmoniAMO 29 Italian Manifesto REFERENCES 1. Tumore del polmone. Dalla diagnosi al dopo cura. [Lung Cancer. FromDiagnosis to Aftercare] Umberto Veronesi Foun- dation for the Advancement of Science. Available from: https://www.fondazioneveronesi.it/magazine/tools-della-salute/ download/i-manuali/tumore-del-polmone-dalla-diagnosi-al-dopo-cura. Last accessed 10 February 2022. 2. Pastorino U, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019;30(7):1162-69. 3. I numeri del cancro in Italia 2021. [Cancer numbers in Italy 2021.] Available from: https://www.aiom.it/wp-content/ uploads/2021/10/2021_NumeriCancro_web.pdf. Last accessed 13 February 2022. 4. Luengo-Fernandez R, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14(12):1165-74. 5. Programma Nazionale Esiti. [National Outcomes Programme.] Edition 2021. Available from: https://pne.agenas.it/main/ doc/Report_PNE_2021.pdf. Last accessed 10 February 2022. 6. Scortichini M, et al. Analisi dei costi diretti del tumore maligno del polmone mediante database amministrativi. [Analysis of direct costs of malignant lung cancer using administrative databases.] Paper presented at the 14th SIHTA national congress, 26-29 October 2021, Virtual congress. 7. Mennini FS. I tumori del polmone: burden sociale e valore dell’innovazione terapeutica. [Lung cancer: a social burden and the value of therapeutic innovation.] Digital Event promoted by CEIS-EEHTA of the University of Rome Tor Vergata and sponsored by Sihta, Rome, 9 November 2021). 8. Gibson GJ, et al. Lung White Book: the economic burden of lung disease. Sheffield: European Respiratory Society 2013; 16-27. 9. Mennini FS. Innovazione e sostenibilità: lo stato dell’arte in oncologia. [Innovation and sustainability: the state of the art in oncology.] Available from: https://www.motoresanita.it/wordpress/wp-content/uploads/2019/12/Francesco-Save- rio-Mennini-Roma-26-novembre-2019.pdf. Last accessed 11 February 2022. 10. Wood R, et al. The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries-a real-world survey of caregivers. Support Care Cancer 2019;27(5):1709-19. 11. Wood R, et al. The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden. Qual Life Res 2019;28(7):1849-61. 12. Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Cancer Cell 2012;21(3): 448.e2. 13. Goldstraw P, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016;11(1):39-51. 14. Hirsch FR, et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017;389: 299-311. 15. Howlader N, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020;383(7):640-649. 16. Tindle HA, et al. Lifetime smoking history and risk of lung cancer: results from the framingham heart study. J Natl Cancer Inst 2018;110(11):1201-207. 17. Il fumo tra gli adolescenti: i dati di Hbsc e Gyts.[Smoking among adolescents: data from Hbsc and Gyts.] Available from: https://www.epicentro.iss.it/fumo/NoTab2012Adolescenti. Last accessed 11 May 2022.